Hydroxychloroquine for the treatment of COVID-19: the importance of scrutiny of positive trials

Ann Palliat Med. 2020 Nov;9(6):3716-3720. doi: 10.21037/apm-20-1538. Epub 2020 Aug 25.

Authors

Ronald Chow¹, Charles B Simone 2nd², Michael Lock³

Affiliations

¹ Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada. ronald.chow@uwo.ca.
² Department of Radiation Oncology, New York Proton Center, New York, NY, USA.
³ Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada.

PMID: 32921099
DOI: 10.21037/apm-20-1538

No abstract available

Publication types

Editorial

MeSH terms

COVID-19 / epidemiology
COVID-19 / virology
COVID-19 Drug Treatment*
Clinical Trials as Topic*
Humans
Hydroxychloroquine / therapeutic use*
SARS-CoV-2 / isolation & purification
United States
United States Food and Drug Administration
Viral Load

Substances

Hydroxychloroquine